丹麦制药公司诺和诺德（Novo Nordisk A/S）周五报告称，该公司下一代减肥药之一monlunabant在较高剂量时减重效果有限，而且有一定副作用，导致该公司股价周五下跌。

消息面上，诺和诺德在官网发布了药物“monlunabant”2a期临床试验的主要结果。整体来看， 与安慰剂相比，该药物具有显著统计学意义的体重减轻。但在较高剂量的组别中，体重额外减轻的效果有限。

Why Corbus Pharmaceuticals sees Novo Nordisk’s controversial approach to obesity drugs as a ticket to a blockbuster.

CB1 receptors Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule approach SAN ...

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...

Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation ...

CB1 receptors Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule approach ...

For instance, in 2008, a weight-loss drug called rimonabant was taken off the market due to its association with an increased ...

Data from the US FDA's Adverse Event Reporting System on tirzepatide showed adverse events generally consistent with those ...

The global pandemic of coronavirus disease 2019 (COVID-19) has exacerbated numerous serious social and health problems, including complications of the disease itself, migration, stress, anxiety, and ...

The device is a variant of Neuralink's brain implant technology, in this case designed to "enable even those who have lost both eyes" to see, according to owner Elon Musk. Separately, progress is ...

Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development ...